BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1418 related articles for article (PubMed ID: 18845497)

  • 1. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
    Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
    Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
    Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
    Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
    Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ductal carcinoma in situ of the breast with close or focally involved margins following breast-conserving surgery: treatment with reexcision or radiotherapy with increased dosage.
    Monteau A; Sigal-Zafrani B; Kirova YM; Fourchotte V; Bollet MA; Vincent-Salomon A; Asselain B; Salmon RJ; Fourquet A
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1021-8. PubMed ID: 19386441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
    Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
    Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
    Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
    Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy.
    Vargas C; Kestin L; Go N; Krauss D; Chen P; Goldstein N; Martinez A; Vicini FA
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1514-21. PubMed ID: 16005576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.
    Rodrigues NA; Dillon D; Carter D; Parisot N; Haffty BG
    Cancer; 2003 Mar; 97(6):1393-403. PubMed ID: 12627502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
    Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
    Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local recurrence rates in breast cancer patients treated with intraoperative electron-boost radiotherapy versus postoperative external-beam electron-boost irradiation. A sequential intervention study.
    Reitsamer R; Peintinger F; Kopp M; Menzel C; Kogelnik HD; Sedlmayer F
    Strahlenther Onkol; 2004 Jan; 180(1):38-44. PubMed ID: 14704843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological response to hormonal manipulation in oestrogen receptor positive ductal carcinoma in situ of the breast.
    Boland GP; McKeown A; Chan KC; Prasad R; Knox WF; Bundred NJ
    Br J Cancer; 2003 Jul; 89(2):277-83. PubMed ID: 12865917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining negative margins in DCIS patients treated with breast conservation therapy: The University of Chicago experience.
    Sahoo S; Recant WM; Jaskowiak N; Tong L; Heimann R
    Breast J; 2005; 11(4):242-7. PubMed ID: 15982389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
    Ottesen GL
    APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
    ; ; Bijker N; Meijnen P; Peterse JL; Bogaerts J; Van Hoorebeeck I; Julien JP; Gennaro M; Rouanet P; Avril A; Fentiman IS; Bartelink H; Rutgers EJ
    J Clin Oncol; 2006 Jul; 24(21):3381-7. PubMed ID: 16801628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
    Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
    Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local recurrence after conservative surgery and radiation therapy for ductal carcinoma in situ: Possible importance of family history.
    Hiramatsu H; Bornstein BA; Recht A; Schnitt SJ; Baum JK; Connolly JL; Duda RB; Guidi AJ; Kaelin CM; Silver EB; Harris JR
    Cancer J Sci Am; 1995; 1(1):55-61. PubMed ID: 9166455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study.
    Benitez PR; Streeter O; Vicini F; Mehta V; Quiet C; Kuske R; Hayes MK; Arthur D; Kuerer H; Freedman G; Keisch M; Dipetrillo T; Khan D; Hudes R
    Am J Surg; 2006 Oct; 192(4):427-33. PubMed ID: 16978943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular predictive factors for local recurrence and distant metastasis of breast cancer after lumpectomy with postoperative radiation therapy.
    Amornmarn R; Bui MM; Prempree TB; Masood S
    Ann Clin Lab Sci; 2000 Jan; 30(1):33-40. PubMed ID: 10678581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
    Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
    Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.